FLT3 and acute myeloid leukemia: In particular, elderly AML/MRC (AML with myelodysplasia-related changes) patients without molecular targets induced by strong driver gene mutations, such as FLT3 (Fms-like tyrosine kinase 3) and IDH2 (isocitrate dehydrogenase 2), continue to have unmet medical therapeutic needs [10].